Prof Demosthenes Katritsis (Hygeia Hospital, Athens, GR) discusses the latest updates from the ESC 2019 guidelines on supraventricular tachycardia (SVT) and anti-arrhythmic drug therapy.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
Arrhythmia
Maximum-Fixed Shocks For Cardioverting Atrial Fibrillation
Dr Anders Sjørslev Schmidt (Aarhus University Hospital, Aarhus, DK) discusses maximum-fixed shocks for cardioverting atrial fibrillation.
Filmed on site at ESC 2019 by Radcliffe Cardiology
Questions
1. What prompted you to conduct this RCT?
2. What was the study design, inclusion criteria, and endpoints studied?
3. Could you summarise your findings?
4. Should this study influence practice and/or further research in these patients?
DGK 2019: The ELIMINATE-AF Trial – Prof Stefan H Hohnloser
Professor Stefan H Hohnloser (J. W. Goethe University, Frankfurt, DE) discusses The ELIMINATE-AF Trial – Uninterrupted Edoxaban versus Vitamin K Antagonists for Ablation of Atrial Fibrillation at DGK 2019.
1.What is the ELIMINATE-AF and why was it initiated?
2.What are the advantages of using NOACs compared to VKAs?
3.What are your findings?
4.What further research, in your opinion, is needed?
5.What are the implications for clinical practice?
Videographers: Mike Knight, Tom Green
Interviewer: Rob Barclay
Filmed on site at DGK 2019 by Radcliffe Cardiology.
HRS 2019: LBB Area Pacing
Dr Pugazhendhi Vijayaraman (Geisinger Heart Institute, Wilkes-Barre, Pennsylvania, US) discusses LBB area pacing – prospective evaluation of feasibility, electrophysiological and echocardiographic characteristics of left bundle branch area pacing.
Filmed on-site by Radcliffe Cardiology at HRS 2019 in San Francisco.
1. Can you tell us about the concept of LBB area pacing?
2. Which patients in your opinion, should benefit most from this technique and what are the main concerns with pacing the LBB region?
3. What data did you present at HRS 2019?
4. What should this mean for clinical practice and subsequent future research?